Clinical Trial Update: Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating adjuvant trastuzumab plus neratinib in hormone receptor-positive, HER2-positive breast cancer after neoadjuvant trastuzumab …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)
• neratinib (neratinib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Early-stage Breast Cancer, HER2-positive Breast Cancer | Phase 3 | Status: RECRUITING